Compare Dow Jones Industrial Average ETF (DIA) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Jones Industrial Average ETF vs GSK plc — how do they compare? Dow Jones Industrial Average ETF trades at $516.07 (market cap $45.20B), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: GSK plc is far larger — about 2× Dow Jones Industrial Average ETF's market cap, and GSK plc pays a 3.9% dividend while Dow Jones Industrial Average ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dow Jones Industrial Average ETF for 104 Days and GSK plc for 93 Days on average.
| DIA | GSK | |
|---|---|---|
Market Cap | $45.20B | $91.88B |
Volume | 4,095,368 | 7,730,529 |
52-Week High | $542.79 | $61.18 |
52-Week Low | $451.37 | $43.24 |
Typical Hold Time | 104 Days | 93 Days |
Sector | — | Health |
Enterprise Value | — | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DIA (SPDR Dow Jones Industrial Average ETF Trust) trades at $511.65 with minimal daily movement (+0.12%). Technical indicators show a bearish bias with moving averages signaling sell pressure, though oscillators remain neutral. The ETF maintains a dividend distribution schedule with recent payouts ranging from $0.15 to $1.19. Market breadth indicators suggest broader market weakness, creating headwinds for this Dow-tracking fund.
The outlook remains cautious given the bearish technical setup and negative market sentiment. Dividend income provides some stability, but the fund faces pressure from declining market breadth and elevated bond yields. Key resistance at $513-516 levels must be breached for bullish momentum to develop.
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
